{
  "kind": "treatment",
  "slug": "methylphenidate-transdermal-daytrana",
  "type": "stimulant",
  "name": "Methylphenidate Transdermal (Daytrana)",
  "summary": "A transdermal methylphenidate patch used to treat attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.",
  "description": "Daytrana is a transdermal patch formulation of methylphenidate that delivers the medication through the skin over approximately 9 hours. It is indicated for ADHD in patients aged 6–17 years. The patch offers an alternative for those who cannot tolerate or swallow oral formulations and allows flexible control of daily duration by adjusting wear time.",
  "category": "medications/stimulants",
  "tags": [
    "adhd",
    "stimulant",
    "transdermal",
    "dopamine",
    "norepinephrine"
  ],
  "metadata": {
    "drug_classes": [
      "CNS Stimulant"
    ],
    "therapeutic_categories": [
      "ADHD"
    ],
    "mechanism_categories": [
      "Other"
    ],
    "administration_routes": [
      "Patch"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": true,
    "generic_available": false,
    "brand_names": [
      "Daytrana"
    ],
    "dea_schedule": "Schedule II (US)",
    "fda_pregnancy_category": "C",
    "age_groups": [
      "Pediatric",
      "Adolescent"
    ],
    "treatment_duration": [
      "Long-term"
    ],
    "specialty_areas": [
      "Psychiatry",
      "Pediatrics"
    ],
    "fda_approval_year": 2006
  },
  "clinical_metadata": {
    "primary_indications": [
      "ADHD"
    ],
    "off_label_uses": [],
    "contraindications": [
      "Marked anxiety, tension, and agitation",
      "Glaucoma",
      "Tics or family history of Tourette's syndrome",
      "MAOI use within 14 days",
      "Hypersensitivity to methylphenidate or patch components"
    ],
    "monitoring_required": [
      "Blood pressure",
      "Heart rate",
      "Growth in children",
      "Signs of misuse or diversion",
      "Skin reactions"
    ],
    "efficacy_rating": {
      "ADHD": 5
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "methylphenidate transdermal",
      "Daytrana",
      "ADHD patch",
      "stimulant"
    ],
    "synonyms": [
      "methylphenidate patch"
    ],
    "common_misspellings": [
      "daytran",
      "methylphenidate patch"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Attention-Deficit/Hyperactivity Disorder (ADHD)"
      ]
    },
    {
      "type": "mechanism",
      "text": "Blocks norepinephrine and dopamine reuptake into presynaptic neurons, increasing their synaptic availability; delivered through the skin for steady absorption."
    },
    {
      "type": "dosing",
      "pediatric": {
        "adhd": "Apply 10 mg patch once daily to hip area, worn for up to 9 hours; adjust dose by patch size (10, 15, 20, 30 mg) at weekly intervals as needed."
      },
      "adult": "Not approved for use",
      "hepatic_impairment": "No specific adjustment; use caution",
      "renal_impairment": "No specific adjustment"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Transdermal patches: 10 mg/9 hr, 15 mg/9 hr, 20 mg/9 hr, 30 mg/9 hr"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Onset: 2 hours after application; duration: approximately 11–12 hours depending on wear time."
    },
    {
      "type": "adverse_effects",
      "common": [
        "decreased appetite",
        "insomnia",
        "nausea",
        "abdominal pain",
        "headache",
        "skin irritation at application site"
      ],
      "less_common": [
        "weight loss",
        "tics",
        "dizziness"
      ],
      "serious": [
        "sudden cardiac death in patients with structural heart abnormalities",
        "psychosis or mania",
        "seizures",
        "permanent skin depigmentation (rare, chemical leukoderma)"
      ]
    },
    {
      "type": "warnings",
      "black_box": "High potential for abuse and dependence.",
      "other": [
        "May increase blood pressure and heart rate—monitor regularly",
        "Chemical leukoderma reported—discontinue if skin color changes occur",
        "Remove patch earlier in day to reduce insomnia risk"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "MAOIs",
          "risk": "Hypertensive crisis",
          "action": "Contraindicated"
        },
        {
          "with": "Antihypertensives",
          "risk": "Reduced efficacy",
          "action": "Monitor BP"
        },
        {
          "with": "Other stimulants",
          "risk": "Increased adverse effects",
          "action": "Avoid combination"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "BP and HR at baseline and periodically",
        "Growth in pediatric patients",
        "Signs of misuse or diversion",
        "Mood and behavior changes",
        "Skin for irritation or depigmentation"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Use if benefits outweigh risks; limited data",
      "lactation": "Excreted in breast milk; monitor infant",
      "pediatrics": "Approved for ages 6–17",
      "geriatrics": "Not studied"
    },
    {
      "type": "tapering",
      "text": "Gradual dose reduction not typically required; remove patch and discontinue use. Abrupt discontinuation may cause fatigue or mood changes."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Apply to clean, dry skin on hip; alternate sides daily",
        "Patch can be removed early to shorten duration of effect",
        "Avoid heat sources over patch site to prevent increased drug absorption"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Daytrana Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "American Academy of Pediatrics ADHD Guidelines",
          "url": "https://www.aap.org/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Methylphenidate Transdermal (Daytrana): ADHD Patch Treatment",
    "description": "Daytrana is a transdermal methylphenidate patch for ADHD in children and adolescents, offering flexible daily wear times and steady absorption."
  }
}
